Studieoverzicht
Study name: RASolve 308: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer
| Histology | |||
|---|---|---|---|
| Tumor stage | |||
| NCT Id | NCT07777822 | ||
| Host / recruiting site 1 | Rijnstate | Enrollment | Planned |
| Therapy line | First line (1L) | ||
| Design |
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet. |
||
| Intervention | DRUG: zoldonrasib oral tablets DRUG: Placebo oral tablets DRUG: pembrolizumab IV infusion or Subcutaneous injection DRUG: pemetrexed + cisplatin /carboplatin IV infusion of either pemetrexed + cisplatin or pemetrexed + carboplatin |
||
| Key outcome parameters |
|
||
| Key inclusion criteria |
|
||
| Key exclusion criteria |
|
||
| Contact information | Log in voor de contactinformatie | ||

